• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

    2/13/24 4:55:55 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABBV alert in real time by email
    SC 13G/A 1 tv0164-abbvieinc.htm SCHEDULE 13G/A abbvieinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 10)*

    Name of issuer:  AbbVie Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  00287Y109

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  00287Y109

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    2,359,434

    7.  SOLE DISPOSITIVE POWER

    152,454,429

    8.  SHARED DISPOSITIVE POWER

    7,925,628

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    160,380,057

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.08%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    AbbVie Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    1 North Waukegan Road
    North Chicago, IL 60064-6400

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    00287Y109

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $ABBV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABBV

    DatePrice TargetRatingAnalyst
    4/22/2025$210.00Overweight
    Cantor Fitzgerald
    12/10/2024$191.00Neutral
    BofA Securities
    12/5/2024$180.00Outperform → Neutral
    Daiwa Securities
    11/22/2024$206.00Market Perform → Outperform
    Leerink Partners
    11/15/2024$205.00Outperform
    Wolfe Research
    11/4/2024Hold → Buy
    Argus
    10/17/2024$203.00Mkt Perform
    Bernstein
    6/5/2024$185.00Hold → Buy
    HSBC Securities
    More analyst ratings

    $ABBV
    SEC Filings

    See more
    • AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AbbVie Inc. (0001551152) (Filer)

      4/25/25 7:48:22 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AbbVie Inc. (0001551152) (Filer)

      4/3/25 4:13:07 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by AbbVie Inc.

      144 - AbbVie Inc. (0001551152) (Subject)

      3/31/25 5:30:00 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABBV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ABBV
    Financials

    Live finance-specific insights

    See more

    $ABBV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

      SC 13G/A - AbbVie Inc. (0001551152) (Subject)

      2/13/24 4:55:55 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

      SC 13G/A - AbbVie Inc. (0001551152) (Subject)

      1/25/24 4:59:27 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AbbVie Inc. (Amendment)

      SC 13G/A - AbbVie Inc. (0001551152) (Subject)

      2/9/23 10:54:46 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie Reports First-Quarter 2025 Financial Results

      Reports First-Quarter Diluted EPS of $0.72 on a GAAP Basis, a Decrease of 6.5 Percent; Adjusted Diluted EPS of $2.46, an Increase of 6.5 Percent; These Results Include an Unfavorable Impact of $0.13 Per Share Related to Acquired IPR&D and Milestones Expense  Delivers First-Quarter Net Revenues of $13.343 Billion, an Increase of 8.4 Percent on a Reported Basis or 9.8 Percent on an Operational Basis  First-Quarter Global Net Revenues from the Immunology Portfolio Were $6.264 Billion, an Increase of 16.6 Percent on a Reported Basis, or 18.1 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $3.425 Billion; Global Rinvoq Net Revenues Were $1.718 Billion; Global Humira Net Revenues

      4/25/25 7:43:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie to Host First-Quarter 2025 Earnings Conference Call

      NORTH CHICAGO, Ill., March 31, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its first-quarter 2025 financial results on Friday, April 25, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas in

      3/31/25 8:00:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity

      Partnership marks AbbVie's entrance into the obesity fieldAgreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for patients in needNORTH CHICAGO, Ill. and HØRSHOLM, Denmark, March 3, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, today announced a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity. "At AbbVie, we are focused on trans

      3/3/25 1:11:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie to Present at the Bank of America Securities Healthcare Conference

      NORTH CHICAGO, Ill., May 6, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 14, 2025. Management will participate in a fireside chat at 12:00 p.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key ther

      5/6/25 8:00:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project"

      BOTOX® Cosmetic Will Provide 250 Entrepreneurs with Access to New Resources and Opportunities and Will Award 20 Grants Worth $20,000 Each to Support Business Goals.By 2030, BOTOX® Cosmetic Pledges to Empower 50,000 Entrepreneurs, Helping to Close the Confidence Gap.IRVINE, Calif., May 1, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced BOTOX® Cosmetic's continued commitment to closing the Confidence Gap with the introduction of The Confidence Project: Empowering Women Entrepreneurs. The one & only BOTOX® Cosmetic invites business owners to apply for this year's program starting today through May 9, 2025, at 11:59pm PT.

      5/1/25 5:00:00 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)

      –      RINVOQ (upadacitinib) is now the first and only oral Janus Kinase (JAK) inhibitor approved for the treatment of GCA in adults–      Also known as temporal arteritis, GCA is the most common vasculitis affecting adults in Western countries2 –      This marks the ninth approved indication for RINVOQ in the U.S., across rheumatology, gastroenterology, and dermatology1 NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA).1 This comes after the European Commission recently granted marketing authoriza

      4/29/25 7:30:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABBV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for VYALEV issued to ABBVIE INC

      Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

      10/18/24 4:38:13 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VYALEV issued to ABBVIE INC

      Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

      10/17/24 1:29:31 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for SKYRIZI issued to ABBVIE INC

      Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:

      6/21/24 4:38:17 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABBV
    Leadership Updates

    Live Leadership Updates

    See more
    • AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

      Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. "I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to

      2/14/25 7:40:00 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

      11/5/24 7:05:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

      11/5/24 7:00:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $ABBV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gonzalez Richard A gifted 2,450 shares, decreasing direct ownership by 0.63% to 386,479 units (SEC Form 4)

      4 - AbbVie Inc. (0001551152) (Issuer)

      4/2/25 5:00:15 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Alpern Robert J

      4 - AbbVie Inc. (0001551152) (Issuer)

      4/2/25 5:00:16 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Quaggin Susan E

      4 - AbbVie Inc. (0001551152) (Issuer)

      4/2/25 5:00:10 PM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABBV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on AbbVie with a new price target

      Cantor Fitzgerald initiated coverage of AbbVie with a rating of Overweight and set a new price target of $210.00

      4/22/25 7:59:33 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities resumed coverage on AbbVie with a new price target

      BofA Securities resumed coverage of AbbVie with a rating of Neutral and set a new price target of $191.00

      12/10/24 8:12:28 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AbbVie downgraded by Daiwa Securities with a new price target

      Daiwa Securities downgraded AbbVie from Outperform to Neutral and set a new price target of $180.00

      12/5/24 7:33:20 AM ET
      $ABBV
      Biotechnology: Pharmaceutical Preparations
      Health Care